Italia - italiano - Ministero della Salute

green remedies spa -

Unione Europea - italiano - EMA (European Medicines Agency)

novartis europharm limited - secukinumab - arthritis, psoriatic; psoriasis; spondylitis, ankylosing - immunosoppressori - plaque psoriasiscosentyx is indicated for the treatment of moderate to severe plaque psoriasis in adults and children from the age of 6 years old who are candidates for systemic therapy. hidradenitis suppurativa (hs)cosentyx is indicated for the treatment of active moderate to severe hidradenitis suppurativa (acne inversa) in adults with an inadequate response to conventional systemic hs therapy. psoriasica arthritiscosentyx, da solo o in combinazione con metotressato (mtx), è indicato per il trattamento dell'artrite psoriasica attiva in pazienti adulti, quando la risposta alla precedente disease-modifying anti-rheumatic drug (dmard), la terapia è stata inadeguata. assiale spondyloarthritis (axspa)spondilite anchilosante, radiografici assiale spondyloarthritis)cosentyx è indicato per il trattamento della spondilite anchilosante attiva in adulti che non hanno risposto in modo adeguato alla terapia convenzionale. non-radiographic axial spondyloarthritis (nr-axspa)cosentyx is indicated for the treatment of active non-radiographic axial spondyloarthritis with objective signs of inflammation as indicated by elevated c-reactive protein (crp) and/or magnetic resonance imaging (mri) evidence in adults who have responded inadequately to non steroidal anti inflammatory drugs (nsaids). juvenile idiopathic arthritis (jia)enthesitis-related arthritis (era)cosentyx, alone or in combination with methotrexate (mtx), is indicated for the treatment of active enthesitis-related arthritis in patients 6 years and older whose disease has responded inadequately to, or who cannot tolerate, conventional therapy. juvenile psoriatic arthritis (jpsa)cosentyx, alone or in combination with methotrexate (mtx), is indicated for the treatment of active juvenile psoriatic arthritis in patients 6 years and older whose disease has responded inadequately to, or who cannot tolerate, conventional therapy.

Italia - italiano - AIFA (Agenzia Italiana del Farmaco)

casen recordati sl - macrogol - macrogol

Italia - italiano - AIFA (Agenzia Italiana del Farmaco)

casen recordati sl - macrogol - macrogol

Italia - italiano - AIFA (Agenzia Italiana del Farmaco)

genetic s.p.a. - prednisone - prednisone

Svizzera - italiano - Swissmedic (Swiss Agency for Therapeutic Products)

novartis pharma schweiz ag - secukinumabum - soluzione iniettabile in siringa preriempita - secukinumabum 150 mg, trehalosum dihydricum, histidinum, histidini hydrochloridum monohydricum, methioninum, polysorbatum 80, aqua ad iniectabile q.s. ad solutionem pro 1 ml. - plaque psoriasis bei erwachsenen und kindern ab 6 jahren, ankylosierende spondylarthritis, psoriatische arthritis, nicht-röntgenologische axiale spondyloarthritis; hidradenitis suppurativa - biotechnologika

Svizzera - italiano - Swissmedic (Swiss Agency for Therapeutic Products)

novartis pharma schweiz ag - secukinumabum - soluzione iniettabile in penna preriempita - secukinumabum 150 mg, trehalosum dihydricum, histidinum, histidini hydrochloridum monohydricum, methioninum, polysorbatum 80, aqua ad iniectabile q.s. ad solutionem pro 1 ml. - plaque psoriasis bei erwachsenen und kindern ab 6 jahren, ankylosierende spondylarthritis, psoriatische arthritis, nicht-röntgenologische axiale spondyloarthritis, hidradenitis suppurativa - biotechnologika

Svizzera - italiano - Swissmedic (Swiss Agency for Therapeutic Products)

novartis pharma schweiz ag - secukinumabum - soluzione iniettabile in siringa preriempita - secukinumabum 300.0 mg, trehalosum dihydricum, histidinum, histidini hydrochloridum monohydricum, methioninum, polysorbatum 80, aqua ad iniectabile q.s. ad solutionem pro 2 ml. - plaque psoriasis bei erwachsenen und kindern ab 6 jahren, ankylosierende spondylarthritis, psoriatische arthritis, nicht-röntgenologische axiale spondyloarthritis; hidradenitis suppurativa - biotechnologika

Svizzera - italiano - Swissmedic (Swiss Agency for Therapeutic Products)

novartis pharma schweiz ag - secukinumabum - soluzione iniettabile in siringa preriempita - secukinumabum 75 mg, trehalosum dihydricum, histidinum, histidini hydrochloridum monohydricum, methioninum, polysorbatum 80, aqua ad iniectabile q.s. ad solutionem pro 0.5 ml. - plaque psoriasis bei erwachsenen und kindern ab 6 jahren, ankylosierende spondylarthritis, psoriatische arthritis, nicht-röntgenologische axiale spondyloarthritis; hidradenitis suppurativa - biotechnologika

Svizzera - italiano - Swissmedic (Swiss Agency for Therapeutic Products)

novartis pharma schweiz ag - secukinumabum - soluzione iniettabile in penna preriempita - secukinumabum 300.0 mg, trehalosum dihydricum, histidinum, histidini hydrochloridum monohydricum, methioninum, polysorbatum 80, aqua ad iniectabile q.s. ad solutionem pro 2 ml. - plaque psoriasis bei erwachsenen, psoriatische arthritis, hidradenitis suppurativa - biotechnologika